Sanofi reported this week that it has inked a deal with Roche for exclusive OTC rights to oseltamivir (Tamiflu) to prevent and treat influenza in the United States. Under the arrangement, Sanofi will be responsible for negotiating the switch to OTC with FDA, as well as marketing, scientific engagement, and U.S. distribution of the product. "This is a strategic and important transaction for us as we strive to continually bring innovations to the market," said Alan Main, executive vice president of consumer health care at Sanofi. "The U.S. market is the largest OTC market in the world and a successful switch of Tamiflu to OTC would support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market." He added, "Tamiflu will offer a significant public health benefit once switched by providing increased access to a safe and efficacious treatment for the prevention and treatment of flu." Roche will continue to market oseltamivir outside the United States, under the agreement, but Sanofi has the rights to first negotiations in certain other markets.
Sanofi signs deal for exclusive OTC rights to oseltamivir
Healio (07/23/2019) Michael, Erin